**ASX Announcement / Media Release**

**13 April 2022**

# First Commercial Pancreas Cancer Treatment With The OncoSil™ Device In Spain

**Key Highlights**

- ✓ **Following numerous implantations in previous clinical studies conducted in Europe, the first commercial treatment with the OncoSil™ device has now been performed in the region;**
- ✓ **The treatment was delivered at The Hospital Universitario de Fuenlabrada in Madrid, Spain;**
- ✓ **Ten hospitals in Spain have been trained in the use of the OncoSil™ device; and**
- ✓ **The OSPREY Patient registry has been granted ethics approval at all of these treatment sites.**

**Sydney, Australia – 13 April 2022:** OncoSil Medical Ltd (ASX: OSL) (**OncoSil** or the **Company**), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer, is pleased to announce the first commercial treatment of the OncoSil™ device in Europe, with the procedure being performed at The Hospital Universitario de Fuenlabrada, located in Madrid, Spain.

The OncoSil team have fully trained 10 hospital sites in Spain for the implantation of the OncoSil™ device. Hospitals in Spain are permitted to negotiate a departmental budget for a specified number of treatments annually. Procurement of the OncoSil™ device is done via a formal tender process for each hospital. The sales team in Spain is currently working with other trained hospitals to facilitate the tender process to enable greater patient access to the OncoSil™ treatment in various regions throughout Spain.

**The Head of Nuclear Medicine at The Hospital Universitario de Fuenlabrada in Madrid, Dr Virginia Peiro said:**

"I am very proud to be involved at Fuenlabrada in the treatment of locally advanced pancreatic cancer patients with this new targeted radionuclide therapy."

**OncoSil's CEO and Managing Director, Mr Nigel Lange said:**

"We are excited to achieve this important milestone for the first commercial patient being treated in Europe. COVID-19 has resulted in lengthy delays in gaining access to hospitals for the OncoSil team to provide training which is of vital importance when treating patients with this new therapy. As restrictions are now beginning to ease, our team have been able to train more hospitals and work with Key Opinion Leaders on the benefits of the OncoSil™ device for patients with locally advanced pancreatic cancer. We look forward to the OncoSil™ device becoming more accessible to patients throughout Spain and subsequently other European countries, to maximise the benefit from this novel treatment. Overall, following our recent success in Germany, we expect the momentum of OncoSil™ device sales to continue improving over the course of the current year."

—END—

**ONCOSIL MEDICAL LIMITED** ABN 89 113 824 141 ASX | OSL
Suite 503, Level 5, 15 Blue Street, North Sydney, NSW 2060 AUSTRALIA
TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9252 3988
WEB www.oncosil.com

## Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.


| Company | Company |
|---|---|
| Mr Nigel Lange<br>CEO & Managing Director<br>E: nigel.lange@oncosil.com<br>T: +49 30 300 149 3043 | Mr Karl Pechmann<br>CFO & Company Secretary<br>E: karl.pechmann@oncosil.com<br>T: +61 2 9223 3344 |


**About OncoSil**

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted six clinical studies with positive results on tolerability, safety and efficacy. CE Marking has been granted for the OncoSil™ device which can be marketed in the European Union and the United Kingdom. The OncoSil™ device has also been classified a Breakthrough Device in the European Union and the United Kingdom.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval.

In December 2018, the FDA granted Humanitarian Use Designation (HUD) for the OncoSil™ device for the treatment of unresectable bile duct cancer. In March 2020, the FDA granted Breakthrough Device Designation for the OncoSil™ for unresectable pancreatic cancer in conjunction with systemic chemotherapy.

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds $3b.

**Forward Looking Statements**

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.